Exagen EBITDA 2011-2026 | XGN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Exagen

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-12 M	-11.9 M	-20.6 M	-44.5 M	-23.2 M	-14.6 M	-8.71 M	-4.74 M	-7.7 M	-	-10.4 M	-11.6 M	-7.66 M	-7.25 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-4.74 M	-44.5 M	-14.2 M

Quarterly EBITDA Exagen

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-2.5 M	-2.13 M	-2.96 M	-	-4.26 M	-2.19 M	-2.5 M	-	-4.47 M	-4.42 M	-7.11 M	-	-7.42 M	-13.8 M	-9.38 M	-	-6.2 M	-5.54 M	-5.37 M	-	-3.69 M	-3.22 M	-5.12 M	-	-2.06 M	-2.21 M	-1.67 M	-	-933 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-933 K	-13.8 M	-4.5 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	1.67 B	$ 114.78	-0.61 %	$ 34.9 B	USA
Biodesix BDSX	-28.7 M	$ 15.7	4.18 %	$ 2.04 B	USA
Biomerica BMRA	-5.05 M	$ 2.15	-0.83 %	$ 4.94 M	USA
BioNano Genomics BNGO	-23.8 M	$ 1.16	-3.33 %	$ 6.32 M	USA
Burning Rock Biotech Limited BNR	-749 M	$ 16.33	0.8 %	$ 176 M	China
CareDx, Inc CDNA	-15.8 M	$ 18.12	-1.04 %	$ 966 M	USA
Celcuity CELC	-172 M	$ 114.33	1.5 %	$ 5.35 B	USA
Aspira Women's Health AWH	-7.8 M	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
Co-Diagnostics CODX	-49.1 M	$ 4.4	101.83 %	$ 5.85 M	USA
Charles River Laboratories International CRL	428 M	$ 166.88	-4.03 %	$ 8.27 B	USA
Castle Biosciences CSTL	24.7 M	$ 25.0	0.64 %	$ 694 M	USA
Check-Cap Ltd. CHEK	-25.8 M	-	-	$ 9.42 M	Israel
Danaher Corporation DHR	5.44 B	$ 191.23	0.06 %	$ 136 B	USA
DexCom DXCM	1.16 B	$ 63.01	1.26 %	$ 24.6 B	USA
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
Fulgent Genetics FLGT	-49 M	$ 16.56	-1.55 %	$ 501 M	USA
Guardant Health GH	-398 M	$ 90.84	-3.19 %	$ 11.4 B	USA
Accelerate Diagnostics AXDX	-12.3 M	-	-61.36 %	$ 2.46 M	USA
ICON Public Limited Company ICLR	1.59 B	$ 111.1	-2.71 %	$ 9.16 B	Irlanda
Interpace Biosciences IDXG	4.51 M	$ 1.92	-1.92 %	$ 8.49 M	USA
Illumina ILMN	-479 M	$ 126.95	-0.34 %	$ 20.2 B	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
IQVIA Holdings IQV	3.33 B	$ 169.58	-2.12 %	$ 29.2 B	USA
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-518 M	-	0.12 %	$ 80.1 M	China
Exact Sciences Corporation EXAS	-81.4 M	-	-	$ 19.8 B	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Laboratory Corporation of America Holdings LH	2.07 B	$ 274.35	0.23 %	$ 22.8 B	USA
Lantheus Holdings LNTH	381 M	$ 75.67	-0.57 %	$ 5.11 B	USA
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
Medpace Holdings MEDP	562 M	$ 494.14	-0.84 %	$ 14.3 B	USA
Mettler-Toledo International MTD	51.1 M	$ 1 256.28	-0.29 %	$ 25.9 B	Schweiz
Myriad Genetics MYGN	-334 M	$ 4.76	0.11 %	$ 441 M	USA
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
ENDRA Life Sciences NDRA	-5.72 M	$ 4.57	-2.46 %	$ 3.6 M	USA
NeoGenomics NEO	-79.8 M	$ 7.98	-0.25 %	$ 1.02 B	USA
Neogen Corporation NEOG	-942 M	$ 9.51	1.01 %	$ 2.06 B	USA
National Research Corporation NRC	30.2 M	$ 17.43	1.6 %	$ 390 M	USA
Natera NTRA	-524 M	$ 204.77	-1.54 %	$ 20.2 B	USA
Pacific Biosciences of California PACB	-541 M	$ 1.41	5.05 %	$ 423 M	USA
Koninklijke Philips N.V. PHG	553 M	$ 27.02	-0.33 %	$ 20 B	Niderland
Precipio PRPO	43 K	$ 26.84	5.67 %	$ 43.1 M	USA
Personalis PSNL	-57.3 M	$ 6.64	0.84 %	$ 393 M	USA
RadNet RDNT	214 M	$ 55.13	0.62 %	$ 4.15 B	USA
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA